PharVision Advisers’s West Pharmaceutical WST Stock Holding History

PharVision Advisers’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,332	Closed	-$291K	–	811
2025 Q2	$291K	Buy	+1,332	New	+$285K	0.42%	86

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

PharVision Advisers's WST Position: Q3 2025 in Review

PharVision Advisers sold out of West Pharmaceutical (WST) in Q3 2025, closing a stake of 1,332 shares — an estimated $291K sold.

PharVision Advisers first reported a position in WST in Q2 2025 and held it in 1 quarter. The position peaked at $291K in Q2 2025. 756 funds tracked by Wall St. Rank hold WST as of Q3 2025.

PharVision Advisers reported no remaining West Pharmaceutical position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 1,332 West Pharmaceutical shares in Q3 2025, an estimated $291K.
PharVision Advisers first reported a position in West Pharmaceutical in Q2 2025 and held it in 1 quarter.
PharVision Advisers's West Pharmaceutical position peaked at $291K in Q2 2025.
756 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.